Amcal to move into pathology screenings

Amcal + shopfront

Amcal is set to offer pathology health screenings in a bid to capture ‘disengaged’ people at risk of health problems

Sigma has announced that it will offer pathology health screenings throughout its Amcal Pharmacy network from June 26, 2017.

In step with Health Minister Greg Hunt’s recently announced focus on preventative health, Sigma plans to provide easy access to Pathology Health Screening and encourage Australians – especially those at risk of chronic diseases – to proactively participate in early detection and wellness screening.

“Preventative health is a focus of the Turnbull Government and is a central part of my National Health Plan.” Health Minister Greg Hunt said earlier this year.

Sigma Pathology Health Screening will be provided in accordance with best practice by SmartHealth utilising their network of 1,500 accredited participating collection centres and laboratories throughout Australia.

Amcal Senior Pharmacist James Nevile says the health screening service will benefit members of the community who are currently disengaged with the traditional healthcare system.

“We recognise the important role that pharmacists play in the Australian healthcare system and are committed to working collaboratively with GPs and other allied healthcare professionals to deliver integrated health care solutions to the community that result in improved health outcomes,” Mr Nevile says.

“In health care, it is essential that patients are the central focus, and our health screening services have been designed to engage or re-engage patients with their GP and the wider health care system united by the common goal of improving health outcomes.”

As part of the Pathology Health Screening Service, Amcal will offer clinical bundles for health screening purposes to customers who meet the criteria. Sigma screenings includes diabetes, heart, kidney, fatigue, vitamin D deficiency and general health and wellbeing bundles.

The tests on offer have been selected in collaboration with SmartHealth’s Pathologist to limit the risk of over screening or unnecessary testing, and to provide patients with the health information they would like to see prior to visiting their GP.

“We believe that GPs and specialists are the most appropriate and qualified to explain and discuss abnormal/out of range pathology results with patients,” says Mr Nevile.

“For this reason, and as with all Sigma’s health screening initiatives, Amcal pharmacists will refer patients to their GP’s and specialist for follow up as appropriate.

“The feedback received from pharmacists and patients has been overwhelmingly positive. Amcal is committed to a collaborative working relationship with all health professionals and health organisations to ensure the Australian public can access effective and efficient health care solutions.”

Sigma says it will continue to invest in innovative health care solutions that directly address the needs of Australian pharmacy patrons.

Previous Social media obsession could be rewiring brains
Next King report suggests direct supply, removing CSO

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.